We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Otsuka and Lundbeck’s Schizophrenia/Depression Drug Gets FDA Green Light
Otsuka and Lundbeck’s Schizophrenia/Depression Drug Gets FDA Green Light
Otsuka and H. Lundbeck expect to launch once-daily Rexulti as a treatment for schizophrenia and add-on therapy for major depressive disorder in early August, following FDA approval Monday.